共 127 条
[1]
Hortobagyi GN(2016)Ribociclib as first-line therapy for HR-positive, advanced breast cancer N Engl J Med 375 1738-1748
[2]
Stemmer SM(2017)MONARCH 3: abemaciclib as initial therapy for advanced breast cancer J Clin Oncol 35 3638-3646
[3]
Burris HA(2015)The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study Lancet Oncol 16 25-35
[4]
Yap YS(2017)MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy J Clin Oncol 35 2875-2884
[5]
Sonke GS(2018)Overall survival with palbociclib and fulvestrant in advanced breast cancer N Engl J Med 379 1926-1936
[6]
Paluch-Shimon S(2018)Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3 J Clin Oncol 36 2465-2472
[7]
Goetz MP(2020)The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial JAMA Oncol 6 116-124
[8]
Toi M(2019)Overall survival with ribociclib plus endocrine therapy in breast cancer N Engl J Med 381 307-316
[9]
Campone M(2022)Overall survival with ribociclib plus letrozole in advanced breast cancer N Engl J Med 386 942-950
[10]
Sohn J(2005)Survival of metastatic breast carcinoma patients over a 20-year period Cancer 104 1742-1750